162 related articles for article (PubMed ID: 34014301)
1. Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy.
Gnocchi D; Castellaneta F; Cesari G; Fiore G; Sabbà C; Mazzocca A
J Pharm Pharmacol; 2021 Sep; 73(10):1369-1376. PubMed ID: 34014301
[TBL] [Abstract][Full Text] [Related]
2.
Gnocchi D; Del Coco L; Girelli CR; Castellaneta F; Cesari G; Sabbà C; Fanizzi FP; Mazzocca A
Sci Rep; 2021 Jan; 11(1):1259. PubMed ID: 33441568
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Hepatocellular Carcinoma Growth by Ethyl Acetate Extracts of Apulian Brassica oleracea L. and Crithmum maritimum L.
Gnocchi D; Cesari G; Calabrese GJ; Capone R; Sabbà C; Mazzocca A
Plant Foods Hum Nutr; 2020 Mar; 75(1):33-40. PubMed ID: 31741122
[TBL] [Abstract][Full Text] [Related]
4. The Edible Plant Crithmum maritimum Shows Nutraceutical Properties by Targeting Energy Metabolism in Hepatic Cancer.
Gnocchi D; Sabbà C; Mazzocca A
Plant Foods Hum Nutr; 2022 Sep; 77(3):481-483. PubMed ID: 35831770
[TBL] [Abstract][Full Text] [Related]
5. Crithmum maritimum Improves Sorafenib Sensitivity by Decreasing Lactic Acid Fermentation and Inducing a Pro-Hepatocyte Marker Profile in Hepatocellular Carcinoma.
Gnocchi D; Sabbà C; Mazzocca A
Plant Foods Hum Nutr; 2023 Mar; 78(1):230-232. PubMed ID: 36525173
[TBL] [Abstract][Full Text] [Related]
6.
Huang XF; Sheu GT; Chang KF; Huang YC; Hung PH; Tsai NM
Molecules; 2020 Nov; 25(23):. PubMed ID: 33266043
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
Yao X; Zhao CR; Yin H; Wang K; Gao JJ
Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Yang X; Liu J; Liang Q; Sun G
Fundam Clin Pharmacol; 2021 Aug; 35(4):690-699. PubMed ID: 33015852
[TBL] [Abstract][Full Text] [Related]
9. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
[TBL] [Abstract][Full Text] [Related]
10. Promotion of HepG2 cell apoptosis by Sedum emarginatum Migo and the mechanism of action.
Qiu Q; Jiang L; Zhen H; Huang F; Zhen D; Ye M; Meng X; Liu Y; Qin X
BMC Complement Med Ther; 2022 Jan; 22(1):31. PubMed ID: 35101006
[TBL] [Abstract][Full Text] [Related]
11. [YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells].
Guo LW; Shao GL; Luo J; Hao WY; Yao Z; Zheng JP
Zhonghua Zhong Liu Za Zhi; 2018 Nov; 40(11):818-823. PubMed ID: 30481931
[No Abstract] [Full Text] [Related]
12. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
[TBL] [Abstract][Full Text] [Related]
13. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
Kim YS; Lee YM; Oh TI; Shin DH; Kim GH; Kan SY; Kang H; Kim JH; Kim BM; Yim WJ; Lim JH
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321984
[TBL] [Abstract][Full Text] [Related]
14. A novel cell cycle blocker extracted from Stellera chamaejasme L. inhibits the proliferation of hepatocarcinoma cells.
Kan XX; Li Q; Chen X; Wang YJ; Li YJ; Yang Q; Xiao HB; Wang ZX; Chen Y; Weng XG; Cai WY; Zhu XX
Oncol Rep; 2016 Jun; 35(6):3480-8. PubMed ID: 27109908
[TBL] [Abstract][Full Text] [Related]
15. Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells.
Seyhoun I; Hajighasemlou S; Ai J; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Parseh B; Abdolahi S; Ghazvinian Z; Shadnoush M; Verdi J
Asian Pac J Cancer Prev; 2019 Jan; 20(1):263-267. PubMed ID: 30678447
[TBL] [Abstract][Full Text] [Related]
16. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment.
Chen B; Pan Y; Xu X; Wu F; Zheng X; Chen SY; Zhao YT; Huang Z; Cheng SH; Liu JX; Wang WH; Li YX
Biomed Pharmacother; 2020 Aug; 128():110284. PubMed ID: 32480224
[TBL] [Abstract][Full Text] [Related]
18. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
Zhao F; Feng G; Zhu J; Su Z; Guo R; Liu J; Zhang H; Zhai Y
Anticancer Drugs; 2021 Apr; 32(4):386-393. PubMed ID: 33395067
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant and apoptotic effects of Callistemon lanceolatus leaves and their compounds against human cancer cells.
Ahmad K; Hafeez ZB; Bhat AR; Rizvi MA; Thakur SC; Azam A; Athar F
Biomed Pharmacother; 2018 Oct; 106():1195-1209. PubMed ID: 30119188
[TBL] [Abstract][Full Text] [Related]
20. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
